Summary
Colorado has recently become the first state to explicitly safeguard neural data privacy, enacting a law on Wednesday, April 17th, 2024. Essentially, this legislation acknowledges that data generated by the nervous system is sensitive.
Supporters in Colorado expressed concerns that without proper safeguards, new devices might enable malicious actors to manipulate an individual's thoughts. Lawmakers in California and Minnesota are similarly evaluating protections for neural data.
Modern healthcare and medical research heavily rely on technology and data. As new technologies emerge, they bring expanded challenges for privacy. The recent move by Colorado demonstrates that regulatory frameworks must remain adaptable and flexible, evolving to cover new scenarios that might not have been envisioned just a few years ago. This is particularly relevant for neurodata and neurotechnology.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
MR-001 CNIL: what clinical trial sponsors must know about French health data compliance
Understand MR-001 CNIL obligations for clinical trial sponsors in France, from Article 32 security requirements to breach notification and cross-border data transfers.
ICF Boilerplate and Open-Access Database Disclosures: What Clinical Trial Sponsors Must Know
Learn how US site ICF boilerplate on commercial products and open-access genetic databases affects sponsor data governance, Common Rule compliance and GDPR obligations.
iliomad Weekly Digest: DPO Conflicts, Bulk Data Rules, Healthcare Cyber Incidents and AI Transparency
This week: CNIL on DPO conflicts of interest, DOJ bulk data rule for life sciences, wave of healthcare ransomware attacks, Uber's €825m GDPR fine and AI disclosure demands.
